Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Vanoxerine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.95 |
| ▸ | TP53 | P04637 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | THPO | P40225 | 2/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vanoxerine SCHEMBL246574 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL725103 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL10000765 | 0.96 | SLC6A4 (0.97) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL15541249 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL6254945 | 0.92 | SLC6A4 (0.90) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| SCHEMBL24221220 | 0.92 | SLC6A4 (0.88) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11374533 | 0.91 | SLC6A4 (0.90) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11380714 | 0.90 | SLC6A4 (0.88) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL11373792 | 0.89 | SLC6A4 (0.83) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 | |
| Vanoxerine SCHEMBL11373788 | 0.89 | SLC6A4 (0.83) | SLC6A4SLC6A3SIGMAR1SLC6A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20100191475-A1 | METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | PERSCHKE SCOTT | 2010-07-29 | — | — | US | disclosed |
| EP-1839222-A2 | A METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | Novascreen Biosciences (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006066219-A2 | A METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | NOVASCREEN BIOSCIENCES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060136140-A1 | Method for identification and functional characterization of agents which modulate ion channel activity | NOVASCREEN BIOSCIENCES | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | SLC6A3 1786/4885SLC6A2 2002/4885SLC6A4 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.